Calprotectin in Rheumatic Diseases: a Review

Overview

Journal Reumatologia

Publisher Termedia

Specialty Rheumatology

Date 2017 Jan 25

PMID 28115781

Citations 20

Authors

Magdalena Kopec-Medrek

Malgorzata Widuchowska

Eugeniusz J Kucharz

Affiliations

Soon will be listed here.

Abstract

Calprotectin also known as MRP8/14 or S100A8/A9 is a heterodimeric complex of two S100 calcium-binding proteins: myeloid-related protein 8 (MRP-8 or S100A8) and MRP-14 (or S100A9). At present, according to many authors, it is considered that calprotectin MRP8/14 is a potentially more sensitive biomarker of disease activity in rheumatoid disease than conventional inflammatory indices such as the erythrocyte sedimentation rate, C-reactive protein and others. A review of the literature on concentration of calprotectin in patients with some rheumatic diseases (rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still's disease, systemic vasculitis, polymyalgia rheumatica, ankylosis spondylitis, systemic lupus erythematosus, and primary Sjögren's syndrome) is presented.

Citing Articles

Proteomic Profile Regulated by the Immunomodulatory Jusvinza Drug in Neutrophils Isolated from Rheumatoid Arthritis Patients.

Hernandez-Cedeno M, Rodriguez-Ulloa A, Ramos Y, Gonzalez L, Serrano-Diaz A, Zettl K Biomedicines. 2025; 12(12.

PMID: 39767648 PMC: 11727316. DOI: 10.3390/biomedicines12122740.

Serum Calprotectin in the Evaluation of Gastrointestinal Diseases: An Ace up Your Sleeve?.

Saviano A, Migneco A, Brigida M, Petruzziello C, Zanza C, Savioli G Medicina (Kaunas). 2024; 60(5).

PMID: 38792945 PMC: 11123171. DOI: 10.3390/medicina60050762.

Serum Levels of S100A8/A9 as a Biomarker of Disease Activity in Patients with IgA Vasculitis.

Srsen S, Held M, Sestan M, Kifer N, Kozmar A, Supe Domic D Biomedicines. 2024; 12(4).

PMID: 38672106 PMC: 11047888. DOI: 10.3390/biomedicines12040750.

Role of serum calprotectin in identifying familial Mediterranean fever attacks.

Polat M, Omma A, Gokcen N, Kilinckaya M, Ozkan Karaahmetoglu S Ir J Med Sci. 2024; 193(4):1901-1909.

PMID: 38478181 DOI: 10.1007/s11845-024-03659-9.

[Methods for assessment of disease activity of polymyalgia rheumatica].

Reisch M, Dejaco C Z Rheumatol. 2023; 82(5):368-379.

PMID: 37184675 PMC: 10264268. DOI: 10.1007/s00393-023-01358-x.

References

Iagnocco A, Finucci A, Ceccarelli F, Perricone C, Iorgoveanu V, Valesini G . Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis. Rheumatology (Oxford). 2015; 54(10):1890-6. DOI: 10.1093/rheumatology/kev211. View

Hirono K, Foell D, Xing Y, Miyagawa-Tomita S, Ye F, Ahlmann M . Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease. J Am Coll Cardiol. 2006; 48(6):1257-64. DOI: 10.1016/j.jacc.2006.02.077. View

Inciarte-Mundo J, Ramirez J, Hernandez M, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba S . Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther. 2016; 18(1):160. PMC: 4938924. DOI: 10.1186/s13075-016-1032-z. View

Garcia-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag M, Jermann T, Cara C . Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort. Mol Diagn Ther. 2013; 17(1):49-56. DOI: 10.1007/s40291-013-0016-9. View

Joshua F, Edmonds J, Lassere M . Power Doppler ultrasound in musculoskeletal disease: a systematic review. Semin Arthritis Rheum. 2006; 36(2):99-108. DOI: 10.1016/j.semarthrit.2006.04.009. View

Haga H, Brun J, Berntzen H, Cervera R, Khamashta M, Hughes G . Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus. 1993; 2(1):47-50. DOI: 10.1177/096120339300200108. View

Krzesiek E . Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children. Adv Clin Exp Med. 2016; 24(5):815-22. DOI: 10.17219/acem/26003. View

Guo Q, Zha X, Li C, Jia Y, Zhu L, Guo J . Serum calprotectin--a promising diagnostic marker for adult-onset Still's disease. Clin Rheumatol. 2015; 35(1):73-9. PMC: 4710651. DOI: 10.1007/s10067-015-3108-6. View

Hammer H, Odegard S, Fagerhol M, Landewe R, van der Heijde D, Uhlig T . Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007; 66(8):1093-7. PMC: 1954700. DOI: 10.1136/ard.2006.064741. View

10.

Tyden H, Lood C, Gullstrand B, Jonsen A, Nived O, Sturfelt G . Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford). 2013; 52(11):2048-55. DOI: 10.1093/rheumatology/ket263. View

11.

Uchida T, Fukawa A, Uchida M, Fujita K, Saito K . Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res. 2003; 1(6):495-9. DOI: 10.1021/pr025531w. View

12.

Inciarte-Mundo J, Hernandez M, Ruiz-Esquide V, Cabrera-Villalba S, Ramirez J, Cuervo A . Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. Arthritis Care Res (Hoboken). 2016; 68(7):899-906. DOI: 10.1002/acr.22795. View

13.

Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen H, Ostergaard M . Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum. 2003; 48(4):955-62. DOI: 10.1002/art.10877. View

14.

Brun J, Madland T, Gran J, Myklebust G . A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity. Scand J Rheumatol. 2005; 34(2):125-8. DOI: 10.1080/03009740410009931. View

15.

Inciarte-Mundo J, Ruiz-Esquide V, Hernandez M, Canete J, Cabrera-Villalba S, Ramirez J . Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology (Oxford). 2015; 54(12):2239-43. DOI: 10.1093/rheumatology/kev251. View

16.

Fagerhol M, Dale I, Andersson T . A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir. 1980; 16 Suppl:273-82. DOI: 10.1016/b978-0-08-027379-2.50028-4. View

17.

Oktayoglu P, Mete N, Caglayan M, Bozkurt M, Bozan T, Em S . Elevated serum levels of calprotectin (MRP8/MRP14) in patients with Behçet's disease and its association with disease activity and quality of life. Scand J Clin Lab Invest. 2014; 75(2):106-12. DOI: 10.3109/00365513.2014.984319. View

18.

Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D . The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009; 60(3):883-91. DOI: 10.1002/art.24349. View

19.

Nordal H, Brun J, Halse A, Madland T, Fagerhol M, Jonsson R . Calprotectin (S100A8/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjögren's syndrome. Scand J Rheumatol. 2013; 43(1):76-8. DOI: 10.3109/03009742.2013.848930. View

20.

Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen M . Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007; 13(9):1042-9. DOI: 10.1038/nm1638. View